Novartis appointed a new Chief Financial Officer, Mehta, amid ongoing strategic execution and financial management. The Swiss pharmaceutical giant slightly lifted its 2025 full-year sales forecast despite second-quarter revenues narrowly missing analyst expectations. The company also announced a $10 billion share buyback plan as it continues to enhance shareholder value. Additionally, BioNTech announced the exit of its chief strategy officer Ryan Richardson, signaling leadership transitions in major biotech corporations. Novartis’ confidence in its pipeline and financial position underscores its commitment to growth and shareholder returns in a competitive global pharmaceutical landscape.